A landmark UK study offers both celebration and a challenge to the rest of the world — including Nigeria.
TheDigger Intelligence Unit
The UK Breakthrough:
A Historic Low The numbers from Britain are genuinely remarkable. According to the latest statistics from Cancer Research UK, between 2022 and 2024, around 247 people per 100,000 died from cancer each year in the UK. This is down from a peak of 355 deaths per 100,000 in 1989 — a decline of nearly 29% over 35 years.
Researchers are clear about what drove this: decades of sustained investment in cancer research, prevention and treatment. It did not happen by accident. It happened by design.
The improvements span multiple cancer types. Over the past ten years alone:
Stomach cancer deaths fell by 34%
Lung cancer deaths dropped by 22%
Ovarian cancer deaths declined by 19%
Breast cancer deaths fell by 14%
Prostate cancer deaths dropped by 11%
Perhaps the most dramatic story is cervical cancer, where deaths have fallen by a staggering 75% since the 1970s — driven by national screening programmes and the HPV vaccine introduced in 2008.
These are not small wins. These are generational transformations, achieved through policy, science and political will.
Now, The Nigerian Reality Check
For decades, a cancer diagnosis in Nigeria has felt like a death sentence. That narrative is slowly — but genuinely — beginning to change. Yet the gap between where Nigeria stands today and where the UK stood in 1989 remains enormous.
Nigeria has no comprehensive national cancer mortality database equivalent to Cancer Research UK’s. That absence itself is part of the problem. You cannot reduce what you do not measure.
What GLOBOCAN data and the Nigerian National System of Cancer Registries do tell us is sobering: Nigeria records roughly 78,000 cancer deaths annually, with cervical, breast, prostate and liver cancers leading the toll. The majority of patients are still diagnosed at Stage 3 or 4 — precisely the stages at which the UK’s investments in early detection have saved the most lives.
Three Lessons Nigeria Must Borrow From the UK Playbook
1. Screening Is the Single Biggest Life-Saver
The UK’s cervical screening programme is credited with detecting cancers before they fully develop — catching pre-cancerous changes early enough to intervene. The HPV vaccine, now given to millions in Britain, has reinforced this by preventing the infections that trigger cervical cancer in the first place.
Nigeria has the ingredients: the Cervical Cancer Free Nigeria initiative, NGO-led HPV vaccination drives through NPHCDA partnerships, and outreach programmes run by organisations like Sebeccly Cancer Care. What is missing is scale and consistency. A screening programme that reaches Lagos Island but not Kebbi State is not a national programme — it is a postcode lottery.
2. Better Treatments Must Reach Everyday Nigerians
In the UK, breakthroughs in hormone-based therapies transformed prostate cancer outcomes. Targeted therapies and personalised medicine are now mainstream, allowing oncologists to match treatment to the biology of a specific tumour.
Nigerian oncologists at LUTH, UCH Ibadan, UNTH Enugu and National Hospital Abuja are aware of these advances. Some are already deploying them. But access remains the bottleneck — insurance gaps, drug availability, and the sheer cost of treatment push most families toward late-stage, emergency-only care. Expanding NHIS coverage for oncology is not a luxury. It is the single policy change most likely to move Nigeria’s cancer mortality curve.
3. Public Health Behaviour Change Works — But Takes Decades
The UK’s falling lung cancer deaths did not happen overnight. Smoking bans, sustained public awareness campaigns and changing social norms around tobacco took 30-plus years to show up fully in the mortality data. Nigeria is at the beginning of a similar journey.
The Tobacco Control Act, growing conversations about diet and obesity, Nollywood storylines tackling cancer stigma, and mosque and church health outreaches are all nudging behaviour in the right direction. The compounding effects of these shifts will take time — but the UK data proves they are real.
The Cancers Still Bucking the Trend — In both Countries
Even in the UK, not all cancers are retreating. Deaths from skin, intestinal, bone and gallbladder cancers have actually risen over the past decade — by as much as 48% in some categories. Liver cancer deaths rose 14%, and kidney cancer by 5%. Lifestyle factors, including tanning bed use and ultra-processed food diets, are implicated.
Nigeria faces its own version of this problem. Liver cancer — strongly linked to hepatitis B, which remains highly prevalent — continues to rise. Colorectal cancer is increasing, tied to rapidly changing diets in urban centres. These are the cancers demanding urgent research attention on both sides of the globe.
The Projection That Should Inspire Nigerian Policymakers
Cancer Research UK projects a further 6% decrease in UK cancer death rates between 2024–26 and 2038–40. That projection is built on the foundation of what has already been invested.
Nigeria’s equivalent projection depends entirely on decisions being made right now — about radiotherapy infrastructure (Nigeria has fewer than 10 functional radiotherapy machines for over 220 million people), about universal health coverage, about research funding, and about whether cancer screening becomes a routine part of primary healthcare rather than an occasional outreach event.
The Bottom Line
The UK took 35 years and relentless systemic investment to cut cancer deaths by nearly a third. Nigeria does not have 35 years to spare — not with a young, rapidly ageing population and cancer incidence rising fast.
But the roadmap exists. The UK has drawn it in data, in policy and in lives saved. The question for Nigeria is simply this: when do we decide to follow it?
